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Abstract
Background: Recently, radiopharmaceutical scanning with Tc-99m-MIBI was reported to depict
areas with active bone disease in multiple myeloma (MM) with both high sensitivity and specificity.
This observation was explained by the uptake of Tc-99m-MIBI by neoplastic cells. The present
investigation evaluates whether Tc-99m-MIBI imaging and magnetic resonance imaging (MRI)
perform equally well in detecting myelomatous bone marrow lesions.
Methods: In 21 patients with MM, MRIs of the vertebral region TH12 to S1 and whole body scans
with Tc-99m-MIBI were done.
Results: Tc-99m-MIBI scanning missed bone marrow infiltration in 43 of 87 vertebrae (50.5%) in
which MRI showed neoplastic bone marrow involvement. In patients with disease stage I+II, Tc-
99m-MIBI scanning was negative in all of 24 vertebrae infiltrated according to MRI. In patients with
disease stage III, Tc-99m-MIBI scanning detected 44 of 63 (70%) vertebrae involved by neoplastic
disease.
Conclusion: Tc-99m-MIBI scanning underestimated the extent of myelomatous bone marrow
infiltration in the spine, especially in patients with low disease stage.
Background
The leading symptom of multiple myeloma (MM) is neo-
plastic bone involvement. Difficulties in diagnosing MM
can arise from the fact that not all patients present with
punched-out osteolytic lesions, the typical radiographic
findings of MM. In 10–20% of patients with first diagno-
sis of MM, the skeletal x-rays are completely normal, and
in up to 10% only osteoporosis-like changes can be
detected. In contrast to skeletal radiography, which
reveals the osseous destruction induced by myeloma cells,
magnetic resonance imaging (MRI) directly depicts the
initiator of bone lesions, myelomatous bone marrow
infiltration [1]. Since bone marrow involvement can be
visualized by MRI, even when the lytic lesions cannot be
seen on skeletal radiographs, MRI has markedly improved
the diagnosis and monitoring of MM [1]. Recently, radi-
opharmaceutical scanning with Technetium-99m 2 meth-
oxy-isobutyl-isonitrile (Tc-99m-MIBI) was shown to
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demonstrate areas with active bone disease in MM with
both high sensitivity and specificity [2-6]. Fonti et al.
reported that myeloma cells directly take up Tc-99m-MIBI
in vitro and that there is a close correlation between both
the in vitro and in vivo uptake of the radiolabeled tracer
and the bone marrow plasma cell infiltration shown by
bone marrow aspiration [6]. Thus, Tc-99m-MIBI scanning
reveals the presence of the infiltrating myeloma cells
rather than its consequence, neoplastic bone destruction.
However, in the studies published yet, the results of Tc-
99m-MIBI scanning have been correlated with plain skel-
etal radiographs and/or with bone scintigraphy, both
examination methods which reveal the neoplastic bone
destruction but not the bone marrow infiltration (as does
MRI). The aim of the present investigation was to evaluate
whether MRI and Tc-99m-MIBI scanning perform equally
well in detecting myelomatous bone marrow lesions in
the spine as an often affected site.
Patients and methods
Twenty-one consecutive patients with MM (15 females, 6
males; median age 68 years, range: 39 – 88 years) partici-
pated in the study. The diagnosis of MM and the staging
of disease were based on standard criteria [7]. Four
patients had disease stage I, 5 disease stage II and 12 dis-
ease stage III. Seventeen patients were entered into the
study at first diagnosis of MM (prior to the first adminis-
tration of chemotherapy or radiotherapy), 4 patients at
disease progression. None of the patients had been irradi-
ated in areas of the spine evaluated for myelomatous bone
marrow infiltration by MRI or Tc-99m-MIBI scanning.
All patients underwent MRI of vertebrae TH12, L1, L2, L3,
L4, L5 and S1. MRI was performed using a 1.0 Tesla Mag-
neton Expert (Siemens) with a spinal coil. Sagittal images
included a T1-weighted spin echo sequence and a fat-sup-
pressed T2-weighted fast spin echo sequence. If a finding
was ambiguous, the T1-weighted images were repeated
after the intravenous injection of gadolinium chelate. All
images were classified into two categories: normal find-
ings and myelomatous involvement (focal, diffuse or het-
erogenous pattern) [1].
Anterior and posterior whole body scans (8 min for each
projection) were obtained ten minutes, 1 hour, 4 hours
and (in four randomly selected patients) 24 hours after
the intravenous injection of 555 MBq of Tc-99m-MIBI. A
large field of view (LFOV) double head gamma camera
(Elscint Helix; Haifa) equipped with a low-energy general
purpose collimator was used. Additionally, one hour after
tracer application, a posterior spot view of the lumbar ver-
tebral column and pelvic area was performed using a low-
energy high resolution collimator. The scans were classi-
fied as showing [3]:
- a normal pattern with only physiological uptake (i.e.,
heart, liver and spleen),
- a pathologic pattern, with areas of focal tracer uptake
and/or diffuse bone marrow uptake.
The two investigators (evaluating either the magnetic res-
onance images or the images obtained by Tc-99m-MIBI
scanning) were blinded with regard to tumor stage and to
the findings by the opposite imaging method.
If MRI or Tc-99m-MIBI scanning revealed several patho-
logic areas in one and the same vertebra of an individual
patient, these were counted as one positive finding for the
respective examination method.
Mononuclear cells isolated from bone marrow aspirates
were available in 16 patients. These cells were stained with
two different monoclonal antibodies that recognize dif-
ferent epitopes of the P-glycoprotein in order to evaluate
the multi drug resistance as a possible reason for missing
Tc-99m-MIBI uptake [8].
The study was performed in accordance with the Declara-
tion of Helsinki, amended by the 29th (Tokyo) and 35th
(Venice) World Medical Assembly, and in accordance
with the pertinent national laws. The protocol was
approved by the local ethical committees. Patients gave
their informed consent prior to enrollment in the study.
Results
In the 21 patients, a total number of 147 vertebrae were
examined. All the lesions found by Tc-99m-MIBI scanning
were already detectable one hour after the administration
of the radiolabelled tracer. The four-hour and 24-hour
examinations did not further improve the results of the
Tc-99m-MIBI scanning. In the entire collective, Tc-99m-
MIBI scanning missed myelomatous bone marrow infil-
tration in 43 of 87 vertebrae (50.5%) in which MRI
showed neoplastic bone marrow involvement (Table 1).
In four patients, Tc-99m-MIBI scanning identified none of
the vertebrae infiltrated according to MRI. Categorizing
patients according to tumor stage revealed that in patients
with disease stage I+II Tc-99m-MIBI scanning was nega-
tive in all of 24 vertebrae in which myelomatous infiltra-
tion was shown by MRI. In patients with disease stage III,
Tc-99m-MIBI scanning detected 44 of 63 (70%) involved
vertebrae. Therefore, the proportion of involved vertebrae
detected by Tc-99m-MIBI scanning was significantly (chi-
square test: p < 0.002) higher in patients with disease
stage III than in patients with disease stage I+II. Tc-99m-
MIBI scanning was positive in only 4 vertebrae (of two
patients with disease stage I) in which MRI showed a nor-
mal structure. In a follow-up of these 2 untreated patientsBMC Nuclear Medicine 2003, 3 http://www.biomedcentral.com/1471-2385/3/2
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two years later, examination by MRI still yielded no signs
of neoplastic infiltration in these 4 vertebrae.
Discussion and Conclusion
In comparison with magnetic resonance imaging, Tc-
99m-MIBI scanning grossly underestimated the extent of
myelomatous bone marrow infiltration, especially in
patients with low disease stage. Since MM is a disease
most often characterized by focal and not diffus neoplas-
tic bone marrow infiltration, random bone marrow sam-
pling may not be entirely diagnostic or predictive of
disease status [7]. Thus, the observation of Fonti et al. who
showed a significant correlation between the intensity of
Tc-99m-MIBI uptake and plasma cell density in bone mar-
row aspirates should be considered with caution. In the
majority of MM patients whose bone marrow is not dif-
fusely infiltrated by neoplastic cells, MRI provides a better
assessment of tumor load, than does single bone marrow
aspiration [9]. However, the advantage of Tc-99m-MIBI
scintigraphy is the image of whole body in one single
examination and it is less time consuming than MRI and
therefore more costeffective and comfortable for the
patient.
According to Tirovola et al. [4], the false negative results of
Tc-99m-MIBI scanning might be due to the presence of
the multidrug resistance associated P-glycoprotein, which
accelerates the efflux of Tc-99m-MIBI (and of several cyto-
statics) from MM cells. In our study, we tested for the pres-
ence of the P-glyocoprotein by means of
immunocytochemistry. In the 16 patients examined
(including three of the four patients with totally negative
Tc-99m-MIBI scans but with lesions detected by MRI) no
evidence of P-glycoprotein expression was found.
Further it must be taken into consideration, that a mild
activity of 99mTc-Tc-99m-MIBI can be observed even in
normal bone and bone marrow [10]. Thus, further pro-
spective studies with Tc-99m-MIBI seem to be necessary in
order to define a reliable scintigraphic pattern, i.e. relative
index to background or to an not affected skeletal area, for
suspected parts of the skeleton as the spine, at which a site
comparison is not possible as for the extremities.
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